Literature DB >> 27047214

The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty.

Eric S Wise1, Stephen P Gadomski2, William G McMaster1, Robert J Wilson1, Justin K Nelms3, Kyle M Hocking1, Colleen M Brophy4.   

Abstract

AIMS: This study characterizes the influence of genotype at two loci on warfarin response after arthroplasty.
METHODS: 121 postarthroplasty patients given warfarin thromboprophylaxis were reviewed for international normalized ratio (INR) values on the first three days postoperatively. Significant differences among genotypes in INR values on each of the first three postoperative days were assessed.
RESULTS: Wild-type patients at both loci (∼23% of patients) had yet to reach therapeutic INR (1.5-2.0) by postoperative day three more frequently than those with a mutation conferring hyper-responsiveness (61% vs. 30%; P ≤ .01).
CONCLUSIONS: Wild-type patients are not anticoagulated in a sufficiently prompt manner after arthroplasty.

Entities:  

Keywords:  Arthroplasty; Deep venous thrombosis; Genetics; Thromboprophylaxis; Warfarin

Year:  2015        PMID: 27047214      PMCID: PMC4796661          DOI: 10.1016/j.jor.2015.10.023

Source DB:  PubMed          Journal:  J Orthop        ISSN: 0972-978X


  26 in total

Review 1.  Prevention of venous thromboembolism.

Authors:  W H Geerts; J A Heit; G P Clagett; G F Pineo; C W Colwell; F A Anderson; H B Wheeler
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.

Authors:  Majid Moridani; Lei Fu; Rita Selby; Francisco Yun; Tatjana Sukovic; Betty Wong; David E C Cole
Journal:  Clin Biochem       Date:  2006-04-21       Impact factor: 3.281

3.  Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.

Authors:  Gwendolyn A McMillin; Roberta Melis; Andrew Wilson; Michael B Strong; Nathan A Wanner; Russell G Vinik; Christopher L Peters; Robert C Pendleton
Journal:  Ther Drug Monit       Date:  2010-06       Impact factor: 3.681

4.  Clinical pharmacogenetics implementation: approaches, successes, and challenges.

Authors:  Kristin W Weitzel; Amanda R Elsey; Taimour Y Langaee; Benjamin Burkley; David R Nessl; Aniwaa Owusu Obeng; Benjamin J Staley; Hui-Jia Dong; Robert W Allan; J Felix Liu; Rhonda M Cooper-Dehoff; R David Anderson; Michael Conlon; Michael J Clare-Salzler; David R Nelson; Julie A Johnson
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-03-10       Impact factor: 3.908

5.  Cost-effective prophylaxis against venous thromboembolism after total joint arthroplasty: warfarin versus aspirin.

Authors:  Reza Mostafavi Tabatabaee; Mohammad R Rasouli; Mitchell G Maltenfort; Javad Parvizi
Journal:  J Arthroplasty       Date:  2014-09-06       Impact factor: 4.757

6.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

7.  Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty.

Authors:  Norman A Johanson; Paul F Lachiewicz; Jay R Lieberman; Paul A Lotke; Javad Parvizi; Vincent Pellegrini; Theodore A Stringer; Paul Tornetta; Robert H Haralson; William C Watters
Journal:  J Am Acad Orthop Surg       Date:  2009-03       Impact factor: 3.020

Review 8.  Venous thromboembolic disease after total hip and knee arthroplasty: current perspectives in a regulated environment.

Authors:  Vincent D Pellegrini; Nigel E Sharrock; Guy D Paiement; Rhys Morris; David J Warwick
Journal:  Instr Course Lect       Date:  2008

9.  Genetic determinants of response to warfarin during initial anticoagulation.

Authors:  Ute I Schwarz; Marylyn D Ritchie; Yuki Bradford; Chun Li; Scott M Dudek; Amy Frye-Anderson; Richard B Kim; Dan M Roden; C Michael Stein
Journal:  N Engl J Med       Date:  2008-03-06       Impact factor: 91.245

10.  Thromboembolic prophylaxis in total joint arthroplasty.

Authors:  David Knesek; Todd C Peterson; David C Markel
Journal:  Thrombosis       Date:  2012-09-16
View more
  1 in total

Review 1.  Drug Response Diversity: A Hidden Bacterium?

Authors:  Nadji Hannachi; Laurence Camoin-Jau
Journal:  J Pers Med       Date:  2021-04-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.